<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03720184</url>
  </required_header>
  <id_info>
    <org_study_id>HARjbm1</org_study_id>
    <nct_id>NCT03720184</nct_id>
  </id_info>
  <brief_title>Haemo-autologous Antegrade Repriming (HAR) as Minimum Impact Perfusion Strategy for Cardiopulmonary Bypass</brief_title>
  <acronym>HARjbm1</acronym>
  <official_title>Haemo-autologous Antegrade Repriming (HAR) Clinical Trial for Validation as Minimum Impact Perfusion Strategy in Cardiopulmonary Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juan Blanco Morillo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitario Virgen de la Arrixaca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Haemo-autologous Antegrade Repriming (HAR) is a procedure based in the combination of
      evidence proven measures designed to reduce the haemodilution caused by establishing the
      cardiopulmonary bypass (CPB) during cardiac surgery.

      This clinical trial aims to determinate, in one hand, the benefits related to HAR in terms of
      transfusion, ICU stay, ventilation time, early mortality and complications. In the other hand
      analyzes the gaseous microemboli (GME) load, comparing the oxygenators venting technology´s
      efficiency in treatment and control group, and its relation with patient´s neurocognitive
      status.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HAR is a repriming technique based in Retrograde Autologous Priming (RAP), that has been
      implemented by recently recommended measures in terms of reducing blood transfusions.

      The expected clinical benefits are related to hemodilution´s reduction up to only 300ml. The
      extracorporeal circuit has been reduced to 3/8 inch diameter in both lines, reducing the
      surface up to 1000ml of dynamic priming.

      Vacuum assisted venous drainage (VAVD) allows to empty the venous line after priming and
      deairing, facilitating the venous flow for CPB initiation.

      The antegrade repriming eliminates the maximum amount of crystalloid contained in the
      circuit, displacing it to a collector bag, by using autologous blood sequestered from the
      arterial line to the hardshell reservoir.

      HAR reduces the CPB hemodilution related to priming from 1500 to 300 ml preventing the usual
      sudden haemoglobin level reduction occured during every extracorporeal techinque´s
      establishment.

      Our mission is to analyze if HAR can be validated as a safe and effective tool to improve
      clinical outcomes in cardiac surgery procedures under extracorporeal circulation
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 15, 2018</start_date>
  <completion_date type="Anticipated">October 13, 2020</completion_date>
  <primary_completion_date type="Actual">September 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>In a preliminary phase, patients are randomly assigned to 4 branches, regarding to two conditions: oxygenator´s deairing type and HAR exposure. This phase is designed as pilot study with 100 patients in order to determine precisely the sample size needed depending on the observed effects.
If there are no clinical differences between oxygenators behaviour, during the second stage, sample will be only divided in 2 groups due to HAR exposure.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Patient and neurocognitive examinator does not know the arm assigned, as well as the anaesthesiologist, surgeon and ICU team. Only the perfusionist has access to de randomization sheet before choosing and set up of the extracorporeal circuit.
In order to guarantee the blinding, the perfusionist must be hidden during the possible HAR performance, using a field blanket to isolate the oxygenator´s area. Anestesiologist´s proceed in every case as if HAR is assigned maintaining a mean arterial pressure over 60 mmHg.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Transfusion</measure>
    <time_frame>1 year</time_frame>
    <description>Blood product consumption during patients hospital stay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ICU stay</measure>
    <time_frame>1 year</time_frame>
    <description>Length of stay at Intensive Care Unit. (days)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventilation time</measure>
    <time_frame>1 year</time_frame>
    <description>Hours under mechanical ventilation after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complications</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of neurological, respiratory, urinary, cardiologic complications and multiorganic failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of death during hospital stay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Emboli number</measure>
    <time_frame>1 year</time_frame>
    <description>Number of total gaseous microemboli delivered by the extracorporeal system to the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emboli Volume</measure>
    <time_frame>1 year</time_frame>
    <description>Volume of total gaseous microemboli delivered by the extracorporeal system to the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotional regulation</measure>
    <time_frame>6 months after surgery</time_frame>
    <description>Evolution of Emotional regulation test results, comparing the variation with the amount of embolic events detected during the extracorporeal procedure. (4-6 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual work memory variation and emboli</measure>
    <time_frame>6 months after surgery</time_frame>
    <description>Evolution of Visuospatial working memory test results, comparing the variation of the basal status and short term measurements (4-6 months after surgery) with the amount of detected emboli delivered to the patient through the heart-lung machine´s circuit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Executive functions and emboli</measure>
    <time_frame>6 months after surgery</time_frame>
    <description>Analysis of the clock drawing test variation, comparing basal and short term (4-6 months after surgery) measurements, and the expected relation with the emboli detected during the extracorporeal technique</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual memory and cognitive status evaluation and emboli</measure>
    <time_frame>6 months after surgery</time_frame>
    <description>Analysis of the variation of cognitive functions using picture tests(comparing basal status and short term evaluation results (4-6 months after surgery) and the amount of emboli delivered to the patient during the cardiopulmonary bypass</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Anemia</condition>
  <condition>Cognitive; Disorder, Due to General Medical Condition</condition>
  <condition>Embolism, Air</condition>
  <condition>Transfusion</condition>
  <condition>Cardiac Disease</condition>
  <condition>Extracorporeal Circulation; Complications</condition>
  <condition>Valve Anomalies</condition>
  <arm_group>
    <arm_group_label>HAR group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treated group is exposed to an haematic antegrade autologous repriming of the circuit, reducing the haemodilution down to 300ml of crystalloid due to the cardiopulmonary bypass initiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group is not exposed to HAR. The extracorporeal circuit is primed with 1000ml of Isofundin (crystalloid balanced solution) as an standard circuit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HAR group 2 (extinguished)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In the begining, there were 4 arms, considering two different types of oxygenator in the two treatment branches, but current analysis did not found signifficant differences between oxygenator types and arms are reduced to HAR and Control Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group (extinguished)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In the begining, there were 4 arms, considering two different types of oxygenator in the two treatment branches, but current analysis did not found signifficant differences between oxygenator types and arms are reduced to HAR and Control Group</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HAR</intervention_name>
    <description>HAR is a procedure that can be performed before the circuit is primed and deaired. The remaining volume in the reservoir as well as the venous line content are displaced to a collector bag that is connected to the oxygenator´s recirculation line.
When the arterial cannula is connected to the patient and the circuit, patient´s blood is used to reprime the arterial line to the oxygenator´s edge, via retrograde, displacing the crystalloid to the collector bag.
Once the arterial line is fully primed with blood, an amount of 300-400ml of patients blood is sequestered to the reservoir preserving a median arterial pressure of 60 mm Hg.
Finally, sequestered blood is used to reprime the arterial pump head and oxygenator-filter pushing the rest of the crystalloid to the collector bag, reducing haemodilution to 300ml.
CPB is established normally, using the vacuum assisted venous drainage not higher than -30 mmHg.</description>
    <arm_group_label>Control Group (extinguished)</arm_group_label>
    <arm_group_label>HAR group</arm_group_label>
    <arm_group_label>HAR group 2 (extinguished)</arm_group_label>
    <other_name>Haemo-autologous antegrade repriming</other_name>
    <other_name>Extracorporeal circuit repriming</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - All patients purposed to undergo elective cardiopulmonary bypass for cardiac valve
        surgery or other pathologies requiring to open heart chambers.

        Exclusion Criteria:

          -  Urgency and emergency

          -  Heart transplantations

          -  Severe cognitive affection

          -  Active sepsis

          -  Previous anemia

          -  Early re-intervention

          -  Pre-Op extracorporeal membrane oxygenation (ECMO) support

          -  Hemodynamic unstability during HAR

          -  Any clinical condition that may force protocol deviation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan B Morillo, M.Sc</last_name>
    <role>Principal Investigator</role>
    <affiliation>IMIB. University Hospital Virgen de la Arrixaca. Murcia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinico universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <state>MU</state>
        <zip>30011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.1186/1471-2377-11-92</url>
    <description>To assess and compare the effectiveness and costs of Phototest,Screen for dementia (DEM) and cognitive impairment (CI).</description>
  </link>
  <link>
    <url>http://www.annalsthoracicsurgery.org/article/S0003-4975(02)03766-9/fulltext</url>
    <description>Effect of blood transfusion on long-term survival after cardiac operation - The Annals of Thoracic Surgery</description>
  </link>
  <link>
    <url>http://linkinghub.elsevier.com/retrieve/pii/S0003497502037669</url>
    <description>Effect of blood transfusion on long-term survival after cardiac operation</description>
  </link>
  <link>
    <url>https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2044.2011.07008.x</url>
    <description>Postoperative cognitive dysfunction is receiving increasing attention, particularly cognitive deficits after cardiac surgery</description>
  </link>
  <reference>
    <citation>Loor G, Rajeswaran J, Li L, Sabik JF 3rd, Blackstone EH, McCrae KR, Koch CG. The least of 3 evils: exposure to red blood cell transfusion, anemia, or both? J Thorac Cardiovasc Surg. 2013 Dec;146(6):1480-1487.e6. doi: 10.1016/j.jtcvs.2013.06.033. Epub 2013 Aug 30.</citation>
    <PMID>23998782</PMID>
  </reference>
  <reference>
    <citation>Liu YH, Wang DX, Li LH, Wu XM, Shan GJ, Su Y, Li J, Yu QJ, Shi CX, Huang YN, Sun W. The effects of cardiopulmonary bypass on the number of cerebral microemboli and the incidence of cognitive dysfunction after coronary artery bypass graft surgery. Anesth Analg. 2009 Oct;109(4):1013-22. doi: 10.1213/ane.0b013e3181aed2bb.</citation>
    <PMID>19762724</PMID>
  </reference>
  <reference>
    <citation>Wang S, Undar A. Vacuum-assisted venous drainage and gaseous microemboli in cardiopulmonary bypass. J Extra Corpor Technol. 2008 Dec;40(4):249-56. Review.</citation>
    <PMID>19192754</PMID>
  </reference>
  <reference>
    <citation>Evered L, Scott DA, Silbert B, Maruff P. Postoperative cognitive dysfunction is independent of type of surgery and anesthetic. Anesth Analg. 2011 May;112(5):1179-85. doi: 10.1213/ANE.0b013e318215217e. Epub 2011 Apr 7.</citation>
    <PMID>21474666</PMID>
  </reference>
  <reference>
    <citation>Zhang X, Yan X, Gorman J, Hoffman SN, Zhang L, Boscarino JA. Perioperative hyperglycemia is associated with postoperative neurocognitive disorders after cardiac surgery. Neuropsychiatr Dis Treat. 2014 Feb 19;10:361-70. doi: 10.2147/NDT.S57761. eCollection 2014.</citation>
    <PMID>24570589</PMID>
  </reference>
  <reference>
    <citation>Segers T, Stehouwer MC, de Somer FMJJ, de Mol BA, Versluis M. Optical verification and in-vitro characterization of two commercially available acoustic bubble counters for cardiopulmonary bypass systems. Perfusion. 2018 Jan;33(1):16-24. doi: 10.1177/0267659117722595. Epub 2017 Aug 2.</citation>
    <PMID>28766987</PMID>
  </reference>
  <reference>
    <citation>Lazar RM, Pavol MA, Bormann T, Dwyer MG, Kraemer C, White R, Zivadinov R, Wertheimer JC, Thöne-Otto A, Ravdin LD, Naugle R, Mechanic-Hamilton D, Garmoe WS, Stringer AY, Bender HA, Kapadia SR, Kodali S, Ghanem A, Linke A, Mehran R, Virmani R, Nazif T, Parhizgar A, Leon MB. Neurocognition and Cerebral Lesion Burden in High-Risk Patients Before Undergoing Transcatheter Aortic Valve Replacement: Insights From the SENTINEL Trial. JACC Cardiovasc Interv. 2018 Feb 26;11(4):384-392. doi: 10.1016/j.jcin.2017.10.041. Epub 2018 Feb 1.</citation>
    <PMID>29397361</PMID>
  </reference>
  <reference>
    <citation>Kurusz M, Butler BD. Bubbles and bypass: an update. Perfusion. 2004;19 Suppl 1:S49-55. Review.</citation>
    <PMID>15161064</PMID>
  </reference>
  <results_reference>
    <citation>Vandewiele K, Bové T, De Somer FM, Dujardin D, Vanackere M, De Smet D, Moerman AT, Bouchez S, François K. The effect of retrograde autologous priming volume on haemodilution and transfusion requirements during cardiac surgery. Interact Cardiovasc Thorac Surg. 2013 Jun;16(6):778-83. doi: 10.1093/icvts/ivt085. Epub 2013 Mar 12.</citation>
    <PMID>23482374</PMID>
  </results_reference>
  <results_reference>
    <citation>Spellman T, Rigotti M, Ahmari SE, Fusi S, Gogos JA, Gordon JA. Hippocampal-prefrontal input supports spatial encoding in working memory. Nature. 2015 Jun 18;522(7556):309-14. doi: 10.1038/nature14445. Epub 2015 Jun 8.</citation>
    <PMID>26053122</PMID>
  </results_reference>
  <results_reference>
    <citation>De Somer FM, Vetrano MR, Van Beeck JP, Van Nooten GJ. Extracorporeal bubbles: a word of caution. Interact Cardiovasc Thorac Surg. 2010 Jun;10(6):995-1001. doi: 10.1510/icvts.2009.229088. Epub 2010 Mar 2.</citation>
    <PMID>20197351</PMID>
  </results_reference>
  <results_reference>
    <citation>Basciani R, Kröninger F, Gygax E, Jenni H, Reineke D, Stucki M, Hagenbuch N, Carrel T, Eberle B, Erdoes G. Cerebral Microembolization During Aortic Valve Replacement Using Minimally Invasive or Conventional Extracorporeal Circulation: A Randomized Trial. Artif Organs. 2016 Dec;40(12):E280-E291. doi: 10.1111/aor.12744. Epub 2016 Jun 10.</citation>
    <PMID>27283935</PMID>
  </results_reference>
  <results_reference>
    <citation>Abrahamov D, Levran O, Naparstek S, Refaeli Y, Kaptson S, Abu Salah M, Ishai Y, Sahar G. Blood-Brain Barrier Disruption After Cardiopulmonary Bypass: Diagnosis and Correlation to Cognition. Ann Thorac Surg. 2017 Jul;104(1):161-169. doi: 10.1016/j.athoracsur.2016.10.043. Epub 2017 Feb 10.</citation>
    <PMID>28193536</PMID>
  </results_reference>
  <results_reference>
    <citation>Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, Saha SP, Song HK, Clough ER; Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion, Shore-Lesserson LJ, Goodnough LT, Mazer CD, Shander A, Stafford-Smith M, Waters J; International Consortium for Evidence Based Perfusion, Baker RA, Dickinson TA, FitzGerald DJ, Likosky DS, Shann KG. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg. 2011 Mar;91(3):944-82. doi: 10.1016/j.athoracsur.2010.11.078. Review.</citation>
    <PMID>21353044</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 18, 2018</study_first_submitted>
  <study_first_submitted_qc>October 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>November 27, 2019</last_update_submitted>
  <last_update_submitted_qc>November 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Virgen de la Arrixaca</investigator_affiliation>
    <investigator_full_name>Juan Blanco Morillo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Retrograde autologous priming</keyword>
  <keyword>RAP</keyword>
  <keyword>HAR</keyword>
  <keyword>cardiopulmonary bypass</keyword>
  <keyword>Extracorporeal circulation</keyword>
  <keyword>Gaseous microemboli</keyword>
  <keyword>perfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Embolism, Air</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

